Stocktoria
Ingevity Corp NGVT
NYSE · XNYS · stock · Chemicals & Allied Products · website · IPO 2016-05-02
Ingevity Corp financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.2B | $1.2B | $1.2B | $1.7B | $1.4B |
| Gross profit | $461.5M | $464.8M | $445.0M | $570.1M | $512.8M |
| R&D expense | $28.4M | $24.5M | $25.4M | $30.3M | $26.3M |
| SG&A expense | $171.2M | $157.8M | $161.8M | $198.8M | $179.3M |
| Operating income | $418.7M | $425.9M | $423.2M | $452.6M | $422.2M |
| Interest expense | $78.3M | $97.8M | $93.3M | $61.8M | $51.7M |
| Income tax | $8.2M | -$19.1M | $24.2M | $58.0M | $44.7M |
| Net income | -$167.1M | -$430.3M | -$5.4M | $211.6M | $118.1M |
| EPS (diluted) | $-4.61 | $-11.85 | $-0.15 | $5.50 | $2.95 |
| Operating cash flow | $331.2M | $128.6M | $205.1M | $313.4M | $293.3M |
| Cash & equivalents | $78.1M | $68.0M | $95.9M | $76.7M | $275.4M |
| Inventory | $186.0M | $195.9M | $308.8M | $335.0M | $241.2M |
| Total assets | $1.7B | $2.0B | $2.6B | $2.7B | $2.5B |
| Total liabilities | $1.6B | $1.8B | $2.0B | $2.0B | $1.8B |
| Shareholders' equity | $29.7M | $195.2M | $631.4M | $698.3M | $673.8M |
Source: SEC EDGAR filings · CIK 0001653477 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.